Found: 22
Select item for more details and to access through your institution.
Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 6, p. 1479, doi. 10.1111/dom.13257
- By:
- Publication type:
- Article
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1781, doi. 10.1111/dom.13114
- By:
- Publication type:
- Article
A time series analysis of government expenditure and health outcomes.
- Published in:
- Journal of Public Health in Africa, 2023, v. 14, n. 7, p. 1, doi. 10.4081/jphia.2023.1409
- By:
- Publication type:
- Article
A hybrid adaptive sampling algorithm for obtaining reduced order models for systems with frequency dependent state-space matrices.
- Published in:
- International Journal of Numerical Modelling, 2016, v. 29, n. 4, p. 741, doi. 10.1002/jnm.2134
- By:
- Publication type:
- Article
Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
- Published in:
- Vascular Health & Risk Management, 2011, v. 7, p. 701, doi. 10.2147/VHRM.S25743
- By:
- Publication type:
- Article
Valsartan: More Than a Decade of Experience.
- Published in:
- Drugs, 2009, v. 69, n. 17, p. 2393, doi. 10.2165/11319460-000000000-00000
- By:
- Publication type:
- Article
Antihypertensive Response to Thiazide Diuretic or Angiotensin Receptor Blocker in Elderly Hypertensives Is Not Influenced by Pretreatment Plasma Renin Activity.
- Published in:
- Cardiovascular Drugs & Therapy, 2012, v. 26, n. 2, p. 145, doi. 10.1007/s10557-011-6365-x
- By:
- Publication type:
- Article
PSO based LQR‐PID output feedback for load frequency control of reduced power system model using balanced truncation.
- Published in:
- International Transactions on Electrical Energy Systems, 2021, v. 31, n. 9, p. 1, doi. 10.1002/2050-7038.13012
- By:
- Publication type:
- Article
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
- Published in:
- Cardiovascular Diabetology, 2020, v. 19, n. 1, p. 1, doi. 10.1186/s12933-020-0991-1
- By:
- Publication type:
- Article
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
- Published in:
- Cardiovascular Diabetology, 2019, v. 18, n. 1, p. 1, doi. 10.1186/s12933-019-0951-9
- By:
- Publication type:
- Article
Optimal load frequency control through combined state and control gain estimation for noisy measurements.
- Published in:
- Protection & Control of Modern Power Systems, 2020, v. 5, n. 1, p. N.PAG, doi. 10.1186/s41601-020-00169-5
- By:
- Publication type:
- Article
Lessons Learned From a Survey of the Diagnosis and Treatment Journeys of Postmenopausal Women With Hypertension.
- Published in:
- Journal of Clinical Hypertension, 2013, v. 15, n. 8, p. 532, doi. 10.1111/jch.12114
- By:
- Publication type:
- Article
Does response of RAS blockade on serum K+ levels influence its glycemic-mitigating response when combined with hydrochlorothiazide?
- Published in:
- 2012
- By:
- Publication type:
- journal article
Does Response of RAS Blockade on Serum K+ Levels Influence Its Glycemic-Mitigating Response When Combined With Hydrochlorothiazide?
- Published in:
- Journal of Clinical Hypertension, 2012, v. 14, n. 7, p. 415, doi. 10.1111/j.1751-7176.2012.00635.x
- By:
- Publication type:
- Article
Office and Ambulatory Blood Pressure-Lowering Effects of Combination Valsartan/Hydrochlorothiazide vs Hydrochlorothiazide-Based Therapy in Obese, Hypertensive Patients.
- Published in:
- Journal of Clinical Hypertension, 2011, v. 13, n. 10, p. 731, doi. 10.1111/j.1751-7176.2011.00499.x
- By:
- Publication type:
- Article
Treating Systolic Hypertension in the Very Elderly With Valsartan-Hydrochlorothiazide vs Either Monotherapy: ValVET Primary Results.
- Published in:
- Journal of Clinical Hypertension, 2011, v. 13, n. 10, p. 722, doi. 10.1111/j.1751-7176.2011.00498.x
- By:
- Publication type:
- Article
Combination Angiotensin-Receptor Blocker (ARB)/Calcium Channel Blocker With HCTZ vs the Maximal Recommended Dose of an ARB With HCTZ in Patients With Stage 2 Hypertension: The Exforge As Compared to Losartan Treatment in Stage 2 Systolic Hypertension (EXALT) Study
- Published in:
- Journal of Clinical Hypertension, 2011, v. 13, n. 8, p. 588, doi. 10.1111/j.1751-7176.2011.00492.x
- By:
- Publication type:
- Article
24-Hour Ambulatory Blood Pressure Response to Combination Valsartan/Hydrochlorothiazide and Amlodipine/Hydrochlorothiazide in Stage 2 Hypertension by Ethnicity: The EVALUATE Study.
- Published in:
- Journal of Clinical Hypertension, 2010, v. 12, n. 11, p. 833, doi. 10.1111/j.1751-7176.2010.00372.x
- By:
- Publication type:
- Article
Improving Blood Pressure Control: Increase the Dose of Diuretic or Switch to a Fixed-Dose Angiotensin Receptor Blocker/Diuretic? The Valsartan Hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve Optimal Therapeutic Effect (Val-DICTATE) Trial
- Published in:
- Journal of Clinical Hypertension, 2008, v. 10, n. 6, p. 450, doi. 10.1111/j.1751-7176.2008.08259.x
- By:
- Publication type:
- Article
Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study.
- Published in:
- European Journal of Preventive Cardiology, 2021, v. 28, n. 17, p. 1864, doi. 10.1093/eurjpc/zwaa097
- By:
- Publication type:
- Article
Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab.
- Published in:
- European Journal of Preventive Cardiology, 2020, v. 27, n. 15, p. 1663, doi. 10.1177/2047487320905185
- By:
- Publication type:
- Article